Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy

Bibliographic Details
Title: Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy
Authors: Tuong Ngoc-Gia Nguyen, Cuong Viet Pham, Rocky Chowdhury, Shweta Patel, Satendra Kumar Jaysawal, Yingchun Hou, Huo Xu, Lee Jia, Andrew Duan, Phuong Ha-Lien Tran, Wei Duan
Source: Pharmaceutics, Vol 15, Iss 8, p 2115 (2023)
Publisher Information: MDPI AG, 2023.
Publication Year: 2023
Collection: LCC:Pharmacy and materia medica
Subject Terms: plant EV, biomarker, pathogen-related proteins, class I chitinase, drug delivery, immunomodulatory, Pharmacy and materia medica, RS1-441
More Details: Over the past decade, there has been a significant expansion in the development of plant-derived extracellular nanovesicles (EVs) as an effective drug delivery system for precision therapy. However, the lack of effective methods for the isolation and characterization of plant EVs hampers progress in the field. To solve a challenge related to systemic separation and characterization in the plant-derived EV field, herein, we report the development of a simple 3D inner filter-based method that allows the extraction of apoplastic fluid (AF) from blueberry, facilitating EV isolation as well as effective downstream applications. Class I chitinase (PR-3) was found in blueberry-derived EVs (BENVs). As Class I chitinase is expressed in a wide range of plants, it could serve as a universal marker for plant-derived EVs. Significantly, the BENVs exhibit not only higher drug loading capacity than that reported for other EVs but also possess the ability to modulate the release of the proinflammatory cytokine IL-8 and total glutathione in response to oxidative stress. Therefore, the BENV is a promising edible multifunctional nano-bio-platform for future immunomodulatory therapies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1999-4923
Relation: https://www.mdpi.com/1999-4923/15/8/2115; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics15082115
Access URL: https://doaj.org/article/7bb4b77c671042b5bc1de0cb9e1268b3
Accession Number: edsdoj.7bb4b77c671042b5bc1de0cb9e1268b3
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:19994923
DOI:10.3390/pharmaceutics15082115
Published in:Pharmaceutics
Language:English